Haruhiro Saito

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 21

Top Topics

Locally Advanced

Tyrosine Kinase

Small Cell Lung Cancer

Top Venues

Thoracic cancer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Taishi Harada, Tomonari Sasaki, Hidenobu Ishii, Shinnosuke Takemoto, Yasushi Hisamatsu, Haruhiro Saito, Yasuto Yoneshima, Kazutoshi Komiya, Kosuke Kashiwabara, Katsuhiko Naoki, Tomohiro Ogawa, Hiroaki Takeoka, Koichi Saruwatari, Kensaku Ito, Yuko Tsuchiya-Kawano, Keiko Mizuno, Takayuki Shimose, Yoshiyuki Shioyama, Isamu Okamoto
A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non-small cell lung cancer (LOGIK1902). Thoracic cancer (2024)
Naoko Shigeta, Shuji Murakami, Tomoyuki Yokose, Tetsuya Isaka, Kanako Shinada, Takuya Nagashima, Hiroyuki Adachi, Shunsuke Shigefuku, Kotaro Murakami, Jun Miura, Noritake Kikunishi, Kozue Watabe, Haruhiro Saito, Hiroyuki Ito
Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer. Thoracic cancer (2024)
Naoko Shigeta, Shuji Murakami, Tomoyuki Yokose, Tetsuya Isaka, Kanako Shinada, Takuya Nagashima, Hiroyuki Adachi, Shunsuke Shigefuku, Kotaro Murakami, Jun Miura, Noritake Kikunishi, Kozue Watabe, Haruhiro Saito, Hiroyuki Ito
Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer. Thoracic cancer 15 (17) (2024)
Naoko Shigeta, Tomoyuki Yokose, Shuji Murakami, Tetsuya Isaka, Kanako Shinada, Emi Yoshioka, Atsuya Narita, Kengo Katakura, Tetsuro Kondo, Terufumi Kato, Takuya Nagashima, Haruhiro Saito, Hiroyuki Ito
Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma". Thoracic cancer 15 (6) (2024)
Naoko Shigeta, Tomoyuki Yokose, Shuji Murakami, Tetsuya Isaka, Kanako Shinada, Emi Yoshioka, Atsuya Narita, Kengo Katakura, Tetsuro Kondo, Terufumi Kato, Takuya Nagashima, Haruhiro Saito, Hiroyuki Ito
Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma". Thoracic cancer 15 (6) (2024)
Naoko Shigeta, Shuji Murakami, Tomoyuki Yokose, Tetsuya Isaka, Kanako Shinada, Takuya Nagashima, Hiroyuki Adachi, Shunsuke Shigefuku, Kotaro Murakami, Jun Miura, Noritake Kikunishi, Kozue Watabe, Haruhiro Saito, Hiroyuki Ito
Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer. Thoracic cancer 15 (17) (2024)
Naoko Shigeta, Shuji Murakami, Tomoyuki Yokose, Tetsuya Isaka, Kanako Shinada, Takuya Nagashima, Hiroyuki Adachi, Shunsuke Shigefuku, Kotaro Murakami, Jun Miura, Noritake Kikunishi, Kozue Watabe, Haruhiro Saito, Hiroyuki Ito
Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer. Thoracic cancer 15 (17) (2024)
Naoko Shigeta, Shuji Murakami, Tomoyuki Yokose, Tetsuya Isaka, Kanako Shinada, Takuya Nagashima, Hiroyuki Adachi, Shunsuke Shigefuku, Kotaro Murakami, Jun Miura, Noritake Kikunishi, Kozue Watabe, Haruhiro Saito, Hiroyuki Ito
Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer. Thoracic cancer 15 (17) (2024)
Naoko Shigeta, Tomoyuki Yokose, Shuji Murakami, Tetsuya Isaka, Kanako Shinada, Emi Yoshioka, Atsuya Narita, Kengo Katakura, Tetsuro Kondo, Terufumi Kato, Takuya Nagashima, Haruhiro Saito, Hiroyuki Ito
Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma". Thoracic cancer 15 (6) (2024)
Naoko Shigeta, Tomoyuki Yokose, Shuji Murakami, Tetsuya Isaka, Kanako Shinada, Emi Yoshioka, Atsuya Narita, Kengo Katakura, Tetsuro Kondo, Terufumi Kato, Takuya Nagashima, Haruhiro Saito, Hiroyuki Ito
Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma". Thoracic cancer 15 (6) (2024)
Naoko Shigeta, Tomoyuki Yokose, Shuji Murakami, Tetsuya Isaka, Kanako Shinada, Emi Yoshioka, Atsuya Narita, Kengo Katakura, Tetsuro Kondo, Terufumi Kato, Takuya Nagashima, Haruhiro Saito, Hiroyuki Ito
Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma". Thoracic cancer 15 (6) (2024)
Naoko Shigeta, Tomoyuki Yokose, Shuji Murakami, Tetsuya Isaka, Kanako Shinada, Emi Yoshioka, Atsuya Narita, Kengo Katakura, Tetsuro Kondo, Terufumi Kato, Takuya Nagashima, Haruhiro Saito, Hiroyuki Ito
Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma". Thoracic cancer (2024)
Chihiro Maeda, Kanako Shinada, Shuji Murakami, Haruhiro Saito
Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M-positive: Case report and literature review. Thoracic cancer (2023)
Hirotsugu Kenmotsu, Nobuyuki Yamamoto, Toshihiro Misumi, Kiyotaka Yoh, Haruhiro Saito, Shunichi Sugawara, Koji Yamazaki, Kazuhiko Nakagawa, Kenji Sugio, Takashi Seto, Shinichi Toyooka, Hiroshi Date, Tetsuya Mitsudomi, Yasuto Yoneshima, Kohei Yokoi, Hideo Saka, Hiroaki Okamoto, Yuichi Takiguchi, Toshiaki Takahashi, Masahiro Tsuboi
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Shuji Murakami, Tomoyuki Yokose, Kanako Shinada, Testuya Isaka, Kengo Katakura, Ryouta Ushio, Tetsuro Kondo, Terufumi Kato, Hiroyuki Ito, Haruhiro Saito
Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations. Thoracic cancer 13 (22) (2022)
Melissa Lynne Johnson, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, Konstantin Laktionov, Sang-We Kim, Grygorii Ursol, Maen Hussein, Farah Louise Lim, Cheng-Ta Yang, Luiz Henrique Araujo, Haruhiro Saito, Niels Reinmuth, Xiaojin Shi, Lynne Poole, Solange Peters, Edward B Garon, Tony S K Mok, null null
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Kanako Shinada, Shuji Murakami, Daisaku Yoshida, Haruhiro Saito
Radiation recall pneumonitis after COVID-19 vaccination. Thoracic cancer (2021)
Makoto Nishio, Haruhiro Saito, Koichi Goto, Satoshi Watanabe, Naoko Sueoka-Aragane, Yusuke Okuma, Kazuo Kasahara, Kenichi Chikamori, Yuki Nakagawa, Tomohisa Kawakami
IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients. Cancer science 112 (4) (2021)
Mitsuhiro Moda, Haruhiro Saito, Terufumi Kato, Ryo Usui, Tetsuro Kondo, Yoshiro Nakahara, Shuji Murakami, Kouji Yamamoto, Kouzo Yamada
Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. Thoracic cancer 11 (12) (2020)
Hiroto Onozawa, Haruhiro Saito, Kuniko Sunami, Takashi Kubo, Noboru Yamamoto, Rika Kasajima, Takashi Ohtsu, Yukihiko Hiroshima, Heiwa Kanamori, Tomoyuki Yokose, Yohei Miyagi
Lung adenocarcinoma in a patient with a cis EGFR L858R-K860I doublet mutation identified using NGS-based profiling test: Negative diagnosis on initial companion test and successful treatment with osimertinib. Thoracic cancer 11 (12) (2020)
Daiji Nemoto, Tomoyuki Yokose, Kayoko Katayama, Shuji Murakami, Terufumi Kato, Haruhiro Saito, Masaki Suzuki, Daisuke Eriguchi, Joji Samejima, Takuya Nagashima, Hiroyuki Ito, Kouzo Yamada, Haruhiko Nakayama, Munetaka Masuda
Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples. Thoracic cancer 12 (2) (2020)